All articles tagged with #acquisition
Originally Published 4 days ago — by WFMZ.com
Keystone Cement, a 100-year-old company in Pennsylvania, is being acquired by Virginia-based Titan America in a $310 million deal, marking its second ownership change in less than a year and expanding Titan's presence in the Mid-Atlantic region.
Originally Published 4 days ago — by Yahoo Finance
Merck is in negotiations to acquire biotech firm Revolution Medicines, with the deal not yet finalized and other bidders potentially involved, causing Revolution's shares to rise.
Originally Published 4 days ago — by Financial Times
Merck is in negotiations to acquire Revolution Medicines, a cancer drug developer, for up to $32 billion, signaling a significant move in the biotech and pharmaceutical industry.
Originally Published 5 days ago — by Snowflake AI Data Cloud
Snowflake plans to acquire Observe to enhance its AI Data Cloud with AI-powered observability solutions, enabling faster troubleshooting, open-standard architecture, and cost-effective telemetry data retention for large-scale AI applications.
Originally Published 5 days ago — by Investor Relations | Paramount
Paramount reaffirmed its commitment to acquire Warner Bros. Discovery with a superior $30 per share all-cash offer, criticizing WBD's current deal with Netflix as less valuable and emphasizing the certainty and full financing of Paramount's bid, despite WBD's decision not to engage.
Originally Published 5 days ago — by Eli Lilly
Eli Lilly is acquiring Ventyx Biosciences in a $1.2 billion all-cash deal to enhance its pipeline of oral therapies targeting inflammation-related diseases across various medical fields, aiming to address high unmet medical needs.
Originally Published 6 days ago — by Financial Times
China is reviewing Meta's $2 billion purchase of the AI startup Manus, raising regulatory questions about the deal.
Originally Published 6 days ago — by Yahoo Finance
Eli Lilly is in advanced negotiations to acquire Ventyx Biosciences for over $1 billion, which would expand Lilly's portfolio to include treatments for inflammatory bowel diseases and other conditions, with an announcement expected soon.
Originally Published 6 days ago — by Reuters
Hg Capital is acquiring financial software company OneStream in a $6.4 billion all-cash deal, resulting in a 28% jump in OneStream's shares. The deal includes minority investments from General Atlantic and Tidemark, and aims to accelerate AI-driven financial forecasting innovations. This follows OneStream's recent IPO and reflects ongoing recovery in global M&A activity despite economic uncertainties.
Originally Published 6 days ago — by Pattern Energy
Pattern Energy is set to acquire Cordelio Power, expanding its renewable energy portfolio across the US and Canada with 1,550 MW of wind, solar, and storage projects, strengthening its position in North America's clean energy sector.
Originally Published 6 days ago — by Yahoo Finance
Hg Capital is acquiring financial software company OneStream in a $6.4 billion all-cash deal, with shareholders receiving $24 per share, leading to a 28% jump in stock price. The deal aims to accelerate OneStream's AI innovation and scale its software offerings, with private equity firm General Atlantic and Tidemark becoming minority investors. This follows OneStream's recent IPO and reflects ongoing recovery in global M&A activity despite economic uncertainties.
Originally Published 6 days ago — by Financial Times
Amgen has announced a deal to acquire a UK-based cancer biotechnology company for up to $840 million, marking a significant expansion in its oncology portfolio.
Originally Published 7 days ago — by Financial Times
Accenture has acquired UK AI start-up Faculty in a deal valued at $1 billion, highlighting its strategic move into artificial intelligence technology.
Originally Published 7 days ago — by Amgen
Amgen has acquired Dark Blue Therapeutics for up to $840 million, adding a novel investigational molecule targeting proteins MLLT1/3 to its oncology pipeline, aiming to improve treatment for acute myeloid leukemia (AML).
Originally Published 7 days ago — by PR Newswire
Amgen has acquired Dark Blue Therapeutics, a UK biotech specializing in targeted protein degraders for oncology, for up to $840 million, to enhance its pipeline for treating acute myeloid leukemia with a novel investigational molecule showing promising preclinical results.